On October 23, 2023, the Food and Drug Administration (FDA) released a new draft guidance that signals an important shift in communications between firms and health care providers. The new communication guidelines center around scientific information on unapproved uses of approved/cleared medical products. The 2023 Draft Guidance is positioned as an update to the FDA’s 2014 draft guidance from which much of the industry’s current practices are built around.
In developing this new draft guidance, the FDA re-emphasizes the necessity of accurate scientific information for health care decision-making. A key point of the new guidelines is the control and limit of ‘off-label’ usage information of products, as they often result in an ethical gray area and create a potential for misuse.
The details and implications of this draft guidance are to be reviewed and understood by corporations and law firms alike given its potential impact on communication dynamics within the health industry. A clear understanding and adaptation of these directives is vital to make sure businesses are conforming with the latest FDA directives.
The new draft, like its 2014 predecessor, is infused with potential for interpretation, and can bring about a variety of responses from firms. How corporations and law firms adapt and interpret the new draft guidance may very well shape the communication landscape regarding unapproved uses of legally approved medical products and equipment.
One theme remains clear – the importance of good reprint practices and solid scientific-based communication is as significant as ever when it comes to conveying information between corporations, law firms, and health care providers. As the industry moves forward, businesses would do well to keep themselves informed and adaptable in the face of these evolving directives.